NKGN

Handel nachbörslich: .28 0.005 +1.82%

Nkgen Biotech Inc (NKGN)

Überblick Nachrichten Preisverlauf Warum fällt NKGN? Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Nkgen Biotech Inc Stock (NKGN) Company Profile

Nkgen Biotech Inc

Healthcare (1171)

Biotechnology (672)

Nächster Verdiensttermin

Neueste SEC-Einreichungen

NKGN's Discussions on Twitter

Vergleichen Sie NKGN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NKGN Nkgen Biotech Inc	0.275	0	0	0	0	0.00
ONC Beigene Ltd Adr	240.41	25.57B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	445.10	111.79B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.30	39.90M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	591.85	65.28B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	73.93	6.31B	0	-153.72M	-103.81M	-2.00

Nkgen Biotech Inc Aktie (NKGN) Neueste Nachrichten

Finanzdaten der Nkgen Biotech Inc-Aktie (NKGN)

Es liegen keine Finanzdaten für Nkgen Biotech Inc (NKGN) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Nkgen Biotech Inc (NKGN)

Nkgen Biotech Inc Stock (NKGN) Company Profile

Vergleichen Sie NKGN mit anderen Aktien

Nkgen Biotech Inc Aktie (NKGN) Neueste Nachrichten

NKGen Biotech Enters Stock Purchase Agreement - TipRanks

NKGen Biotech Delays Quarterly Report Filing - TipRanks

NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally - GlobeNewswire

NKGen Biotech’s Strategic Stock Purchase Agreement - TipRanks

NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations - Stock Titan

NKGen Biotech to Present Phase 1 Clinical Data on Troculeucel for Alzheimer's Disease at ASGCT Annual Meeting - Nasdaq

NKGen Biotech to Present Troculeucel Clinical and Biomarker - GlobeNewswire

NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting - Stock Titan

Head-To-Head Review: NKGen Biotech (NYSE:NKGN) and Athira Pharma (NASDAQ:ATHA) - Defense World

NKGen Biotech secures amended loan terms with East West Bank By Investing.com - Investing.com India

NKGen Biotech secures amended loan terms with East West Bank - Investing.com

NKGen Biotech (NYSE:NKGN) Trading Up 4.3% – Here’s What Happened - Defense World

NKGen Biotech To Present on the Use of Troculeucel for - GlobeNewswire

Breakthrough NK Cell Therapy Data Reveals New Hope for Alzheimer's Patients - Stock Titan

NKGen Biotech Presents Data from Phase 1/2a Clinical Trial - GlobeNewswire

NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer’s Disease at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025) - Yahoo

NKGen Biotech Delays Annual Report Filing - TipRanks

3 Stocks Near 52-Week Lows With Strong Rebound Potential - The Globe and Mail

NKGen Biotech to Present Phase 1 Results on Troculeucel NK Cell Therapy for Alzheimer's at AD/PD™ 2025 Conference - Nasdaq

NKGen Biotech To Present Updated Troculeucel Data at the - GlobeNewswire

Groundbreaking NK Cell Therapy Data for Alzheimer's: 6-Month Results to be Revealed at Major Conference - Stock Titan

Biotech Alert: Searches spiking for these stocks today - Yahoo Finance

NKGen Biotech To Present on Potential of Troculeucel for - GlobeNewswire

NKGen Biotech to Present Troculeucel as Potential Neurodegenerative Disease Therapy at Alzheimer’s & Parkinson’s Drug Development Summit - Nasdaq

NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer’s & Parkinson’s Drug Development Summit - GlobeNewswire

Revolutionary NK Cell Therapy Advances Against Alzheimer's: FDA Fast-Tracks Promising Treatment - StockTitan

NKGen Biotech secures $5 million convertible loan By Investing.com - Investing.com South Africa

NKGen Biotech secures $5 million convertible loan - Investing.com India

4 Biotech Stocks To Watch: CVM, NKGN, NBIO, IMUX - DRP Journal

NKGen Biotech moving to OTC Markets, cancels 1-for-6 reverse stock split - TipRanks

NKGen Biotech shifts to OTC Markets after Nasdaq delisting By Investing.com - Investing.com South Africa

NKGen Biotech shifts to OTC Markets after Nasdaq delisting - Investing.com India

NKGen Biotech, Inc. to Transition from the Nasdaq Global - GlobeNewswire

NKGen Biotech Delisted: What Happens to Its FDA Fast-Tracked Alzheimer's Program Now? - StockTitan

NKGen Biotech, Inc. SEC 10-Q Report - TradingView

Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program - Marketscreener.com

NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program - The Manila Times

NKGen Biotech announces administration of first dose of troculeucel - TipRanks

Can NK Cell Therapy Help Stroke Patients? NKGen's FDA-Cleared Treatment Begins Testing - StockTitan

NKGen Biotech Doses First FTD Patient With Troculeucel Under FDA Compassionate Use - Nasdaq

NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program - Marketscreener.com

NKGen Biotech Announces Administration of First Dose of - GlobeNewswire

Groundbreaking Brain Barrier-Crossing Treatment Starts in Frontotemporal Dementia PatientWill NK Cells Change Neurology? - StockTitan

NKGen Biotech Inc (NKGN) At $0.48: It’s Worth Your Interest - Stocks Register

NKGen Appoints Dr. Anita Fletcher as National Principal - GlobeNewswire

NKGen Appoints Dr. Anita Fletcher As National Principal Investigator For Phase 2A Troculeucel Trial Evaluating Moderate Alzheimer'S Disease With Adventhealth Orlando As First East Coast Site - Marketscreener.com

Can This NK Cell Therapy Transform Alzheimer's Treatment? Phase 1 Shows Remarkable 90% Success - StockTitan

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Midday Stock Roundup: RxSight Down 6.1% on Weak Post-3Q Results - Orange County Business Journal

FDA fast tracks NKGen's Alzheimer's therapy troculeucel - MSN

Finanzdaten der Nkgen Biotech Inc-Aktie (NKGN)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie NKGN